Neuland Laboratories completes USFDA inspection at Unit 2
Drug Approval

Neuland Laboratories completes USFDA inspection at Unit 2

The FDA issued Form 483 with one observation related to building and facility management

  • By IPP Bureau | May 03, 2025

The United States Food and Drug Administration (USFDA) has inspected Neuland Laboratories Limited's Unit 2 manufacturing facility, located at Pashamylaram village, Sangareddy District, from April 28, 2025 to May 2, 2025.

The FDA issued Form 483, with one observation related to building and facility management, which the company will respond to within the stipulated timelines.

Upcoming E-conference

Other Related stories

Startup

Digitization